ClinicalTrials.gg
CompletedNCT01745159Updated Aug 5, 2014

Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis

A Phase 4 interventional study of tacrolimus in Moderate/Severe Atopic Dermatitis, sponsored by Astellas Pharma China, Inc.. Completed at 4 sites in China. Open to participants aged 2 Years to 15 Years. Per ClinicalTrials.gov, last updated 2014-08-05.

Sponsored by Astellas Pharma China, Inc. (part of Astellas Pharma Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
2 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing tacrolimus in Lymphoma, Follicular — none open to participants now, none under way, none of them phase 3. Tacrolimus · Lymphoma, Follicular.

Enrollment
5th of 23
125 · median 41
Started
2012
with 1 other
Phase 4
Only one
of the 26
Registered
21st of 26
by date
Lead sponsor
1 of 26
Astellas Pharma China, Inc.

Among the 26 studies testing tacrolimus in Lymphoma, Follicular, this one is the 5th largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2012, is the only one in phase 4, and was the 21st registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

None of the 26 studies testing tacrolimus in Lymphoma, Follicular is open now. The open studies under Lymphoma, Follicular, anywhere →

Where they have run

About tacrolimus

Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 2 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing tacrolimus in Lymphoma, Follicular as a file.
02

Study summary

To assess if proactive, 2 times-weekly application of tacrolimus ointment can extend remission time to relapse and reduce the incidence of disease exacerbation (DE) in paediatric patients over a period of 6 months.

Read the detailed description

This study includes three periods. First a screening period of up to one week. Second an open-label treatment period of up to six weeks where all participants apply tacrolimus ointment. Third an open-label disease control period of up to six months where half of the participants apply tacrolimus ointment and the other half of the participants do not apply treatment.

03

Conditions studied

  • Moderate/Severe Atopic Dermatitis

Keywords

  • tacrolimus
  • Protopic
  • pediatric
  • atopic dermatitis
  • China
04

Who can participate

Ages eligible
2 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Diagnosed as AD according to Williams diagnostic criteria.
  2. Moderate or severe atopic dermatitis according to the criteria of Rajka and Langeland
  3. At least approximately 10 % of body area
  4. Patient is able to reach the centre within 3 days in case of a disease exacerbation.
  5. Patient's legal representative(s) has/have given written . If the patient is capable of understanding the purposes and risks of the trial, written informed consent has been obtained from the patient as well
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    continued tacrolimus treatment

    children with moderate/severe atopic dermatitis treated with tacrolimus ointment and continuing to apply tacrolimus ointment during disease control period.

    Drug: tacrolimus

  • No intervention
    no additional treatment

    children with moderate/severe atopic dermatitis treated with tacrolimus ointment and with no additional treatment during disease control period.

Interventions

06

What researchers measure

Primary outcomes

  1. Time to first DE (disease exacerbation)

    Time frame: 6 months of DCP(Disease Control Period) after 2 to 6 weeks of OLP(Open Label Period)

Secondary outcomes

  1. Number of DEs during the DCP

    Time frame: 6 months of DCP (Disease Control Period)

  2. Eczema Area and Severity Index (EASI)

    Time frame: 6 months of DCP (Disease Control Period) after 2 to 6 weeks of OLP (Open Label Period)

  3. Investigator's Global Assessment (IGA)

    Time frame: 6 months of DCP (Disease Control Period) after 2 to 6 weeks of OLP (Open Label Period)

  4. Duration of DE during DCP

    Time frame: 6 months of DCP (Disease Control Period)

  5. The overall efficacy during OLP

    Time frame: After 2 to 6 weeks of OLP (Open Label Period)

  6. Quantity of tacrolimus ointment used

    Time frame: 6 months of DCP (Disease Control Period) after 2 to 6 weeks of OLP (Open Label Period)

  7. Incidence of adverse events

    Time frame: 6 months of DCP (Disease Control Period) after 2 to 6 weeks of OLP (Open Label Period)

07

Study locations

4 sites
  • Beijing, China
  • Chongqing, China
  • Guangzhou, China
  • Shanghai, China
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2012
First posted
Dec 10, 2012
Start
Sep 2012
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Last update
Aug 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01745159
Responsible party
Sponsor
First posted
Dec 10, 2012
Start date
Sep 2012
Primary completion
Nov 2013
Completion
Nov 2013
Last update
Aug 5, 2014

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion